高水平的T细胞耗竭和尿肿瘤DNA水平与非肌层浸润性膀胱癌患者卡介苗治疗失败相关
该研究纳入156例接受卡介苗(BCG)治疗的NMIBC患者,用多组学分析BCG治疗后高级别复发的分子相关因素。BCG后T细胞耗竭与高级别复发相关(p=0.002),BCG后tdDNA未清除者复发风险高(p=0.018),尿免疫抑制蛋白可提示复发。
要点
- BCG后T细胞耗竭与高级别复发相关(p=0.002)。
- BCG前肿瘤高耗竭评分与较差BCG后无高级别复发生存相关(p=0.002)。
- BCG后tdDNA未清除识别高复发风险患者(p=0.018)。
核心结论
- BCG后高级别复发可能由T细胞耗竭引起。
- 肿瘤亚型和BCG前肿瘤特征可能识别BCG后高级别复发高危患者。
- 尿液检测有潜力实时评估治疗反应。
研究设计与样本
- 研究纳入接受BCG治疗的NMIBC患者156例。
- 对异时性肿瘤进行RNA测序(n=170)和全外显子组测序(n=195)。
- 尿液样本分析免疫肿瘤相关蛋白(n=190)和肿瘤来源DNA(tdDNA;n=187)。
- 主要终点为BCG后高级别复发,采用Cox回归、Wilcoxon秩和检验、t检验和Fisher精确检验分析。
主要发现
- BCG诱导免疫系统激活,与临床反应无关;但BCG后高级别复发患者尿中观察到免疫抑制蛋白(CD70、PD1、CD5)。
- BCG后高级别复发与BCG后T细胞耗竭相关(p=0.002)。
- BCG后T细胞耗竭患者的BCG前肿瘤高表达细胞分裂和免疫功能相关基因。
- BCG前肿瘤高预测BCG后耗竭评分与较差的BCG后无高级别复发生存(HGRFS)相关(p=0.002),并在独立队列中验证。
- BCG前2a和2b类肿瘤(UROMOL2021方案)与较差的BCG后HGRFS相关(p=0.015)。
局限性
- 回顾性设计。
- 分析之间存在部分重叠。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The functional status of immune cells in the tumor microenvironment and tumor characteristics may explain bacillus Calmette-Guérin (BCG) failure in high-risk non-muscle-invasive bladder cancer (NMIBC). OBJECTIVE: To characterize molecular correlates of post-BCG high-grade (HG) recurrence using multiomics analysis. DESIGN, SETTING, AND PARTICIPANTS: Patients with BCG-treated NMIBC (n = 156) were included in the study. Metachronous tumors were analyzed using RNA sequencing (n = 170) and whole-exome sequencing (n = 195). Urine samples were analyzed for immuno-oncology-related proteins (n = 190) and tumor-derived DNA (tdDNA; n = 187). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was post-BCG HG recurrence. Cox regression and Wilcoxon rank-sum, t, and Fisher's exact tests were used for analyses. RESULTS AND LIMITATIONS: BCG induced activation of the immune system regardless of clinical response; however, immunoinhibitory proteins were observed in the urine of patients with post-BCG HG recurrence (CD70, PD1, CD5). Post-BCG HG recurrence was associated with post-BCG T-cell exhaustion (p = 0.002). Pre-BCG tumors from patients with post-BCG T-cell exhaustion had high expression of genes related to cell division and immune function. A high predicted post-BCG exhaustion score for pre-BCG tumors was associated with worse post-BCG HG recurrence-free survival (HGRFS; p = 0.002). This was validated in independent cohorts. Pre-BCG class 2a and 2b tumors (UROMOL2021 scheme) were associated with worse post-BCG HGRFS (p = 0.015). Post-BCG exhaustion was observed in patients with high pre-BCG neoantigen load (p = 0.017) and MUC4 mutations (p = 0.002). Finally, the absence of post-BCG tdDNA clearance identified patients at high risk of recurrence (p = 0.018). The retrospective design and partial overlap for analyses are study limitations. CONCLUSIONS: Post-BCG HG recurrence may be caused by T-cell exhaustion. Tumor subtype and pre-BCG tumor characteristics may identify patients at high risk of post-BCG HG recurrence. Urinary measurements have potential for real-time assessment of treatment response. PATIENT SUMMARY: A dysfunctional immune response to bacillus Calmette-Guérin (BCG) therapy may explain high-grade recurrences of bladder cancer.
引用
- Strandgaard T, Lindskrog SV, Nordentoft I, et al. Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Guérin Failure in Patients with Non-muscle-invasive Bladder Cancer. Eur Urol. 2022. PMID: 36210217. doi:10.1016/j.eururo.2022.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。